Damian Garde

Neurocrine Biosciences Inc. plunged early Wednesday after a study of its experimental schizophrenia treatment was disappointing when compared to a rival medicine that's likely to hit the market much sooner.

Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a head-to-head study, a finding that could change the standard of care for one of the most deadly tumor types.

Pfizer Inc.’s dispute with activist firm Starboard Value LP isn’t “an aggressive situation,” Chief Executive Officer Albert Bourla said, months after the feared investor disclosed a stake in the company and questioned his management.

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top-selling medicine from pricing pressure.

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over a decade.

By Ike Swetlitz and Damian Garde | Bloomberg The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and

The U.S. plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy , the latest drugs to be targeted under legislation that's expected save the government more than $200 billion over a decade.

Hi all, it’s Damian, Madison, Naomi, Gerry and Bob, and we all spent last week in San Francisco at the JPMorgan Healthcare Conference searching for decent Wi-Fi, dodging Waymos and overpaying for drinks.

(Bloomberg) -- Johnson & Johnson beat Wall Street's fourth-quarter expectations as strong cancer drug sales compensated for a decline in demand for the company's blockbuster psoriasis treatment.